Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AVR NASDAQ:BWAY NASDAQ:DRTS NASDAQ:INGN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVRAnteris Technologies Global$6.32-3.0%$5.90$2.85▼$6.95$614.98M1.321.10 million shs131,598 shsBWAYBrainsway$17.10+2.4%$14.27$4.31▼$17.18$684.28M1.23186,978 shs18,488 shsDRTSAlpha Tau Medical$8.03+2.2%$7.38$2.57▼$9.07$685.35M1.11367,224 shs80,281 shsINGNInogen$7.34+2.0%$6.50$5.34▼$9.13$199.92M1.64282,718 shs356,126 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVRAnteris Technologies Global+1.88%+5.85%+22.37%+18.58%+61.54%BWAYBrainsway+1.83%+0.91%+36.30%+53.44%+284.58%DRTSAlpha Tau Medical+3.43%-5.88%+9.94%+10.41%+188.60%INGNInogen+1.13%+1.13%+5.74%+27.03%+0.28%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAVRAnteris Technologies Global$6.32-3.0%$5.90$2.85▼$6.95$614.98M1.321.10 million shs131,598 shsBWAYBrainsway$17.10+2.4%$14.27$4.31▼$17.18$684.28M1.23186,978 shs18,488 shsDRTSAlpha Tau Medical$8.03+2.2%$7.38$2.57▼$9.07$685.35M1.11367,224 shs80,281 shsINGNInogen$7.34+2.0%$6.50$5.34▼$9.13$199.92M1.64282,718 shs356,126 shs7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Click the link to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAVRAnteris Technologies Global+1.88%+5.85%+22.37%+18.58%+61.54%BWAYBrainsway+1.83%+0.91%+36.30%+53.44%+284.58%DRTSAlpha Tau Medical+3.43%-5.88%+9.94%+10.41%+188.60%INGNInogen+1.13%+1.13%+5.74%+27.03%+0.28%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAVRAnteris Technologies Global 2.50Moderate Buy$15.33142.81% UpsideBWAYBrainsway 3.25Buy$15.00-12.30% DownsideDRTSAlpha Tau Medical 2.20Hold$8.678.00% UpsideINGNInogen 2.67Moderate Buy$13.0077.23% UpsideCurrent Analyst Ratings BreakdownLatest INGN, DRTS, BWAY, and AVR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/24/2026BWAYBrainsway Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold (C) ➝ Buy (B-)4/20/2026DRTSAlpha Tau Medical Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/7/2026INGNInogen Freedom CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy3/27/2026AVRAnteris Technologies Global Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight$15.003/24/2026BWAYBrainsway Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy3/12/2026AVRAnteris Technologies Global Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$15.003/12/2026BWAYBrainsway HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$30.00 ➝ $15.003/11/2026AVRAnteris Technologies Global Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$16.003/11/2026DRTSAlpha Tau Medical CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$7.00 ➝ $9.003/10/2026DRTSAlpha Tau Medical HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$12.003/4/2026AVRAnteris Technologies Global Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy(Data available from 5/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAVRAnteris Technologies Global$1.91M321.47N/AN/A($0.01) per share-631.50BWAYBrainsway$52.23M13.11$0.24 per share70.09$1.87 per share9.15DRTSAlpha Tau MedicalN/AN/AN/AN/A$0.91 per shareN/AINGNInogen$348.67M0.57N/AN/A$7.08 per share1.04Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAVRAnteris Technologies Global-$94.14M-$2.56N/AN/AN/A-4,921.27%-536.04%-267.57%5/12/2026 (Estimated)BWAYBrainsway$7.57M$0.2568.3738.01N/A14.62%11.10%6.97%5/13/2026 (Estimated)DRTSAlpha Tau Medical-$42.63M-$0.53N/AN/AN/AN/A-57.29%-42.39%5/18/2026 (Estimated)INGNInogen-$22.75M-$0.86N/AN/AN/A-6.52%-11.56%-7.42%N/ALatest INGN, DRTS, BWAY, and AVR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/18/2026Q1 2026DRTSAlpha Tau Medical-$0.13N/AN/AN/A$0.05 millionN/A5/13/2026Q1 2026BWAYBrainsway$0.05N/AN/AN/A$14.63 millionN/A5/12/2026Q1 2026AVRAnteris Technologies Global-$0.2708N/AN/AN/A$0.77 millionN/A5/7/2026Q1 2026INGNInogen-$0.24-$0.30-$0.06-$0.30$82.35 million$85.11 million3/11/2026Q4 2025BWAYBrainsway$0.11$0.14+$0.03$0.14$14.02 million$14.55 million3/9/2026Q4 2025DRTSAlpha Tau Medical-$0.13-$0.14-$0.01-$0.92$0.06 millionN/A2/26/2026H2 2025AVRAnteris Technologies GlobalN/A-$0.75N/A-$0.75N/A$0.31 million2/24/2026Q4 2025INGNInogen-$0.36-$0.26+$0.10-$0.26$82.00 million$81.72 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthAVRAnteris Technologies GlobalN/AN/AN/AN/AN/ABWAYBrainswayN/AN/AN/AN/AN/ADRTSAlpha Tau MedicalN/AN/AN/AN/AN/AINGNInogenN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAVRAnteris Technologies Global0.010.730.73BWAYBrainswayN/A3.733.44DRTSAlpha Tau Medical0.087.457.45INGNInogenN/A3.122.71Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAVRAnteris Technologies GlobalN/ABWAYBrainsway30.11%DRTSAlpha Tau Medical2.65%INGNInogen89.94%Insider OwnershipCompanyInsider OwnershipAVRAnteris Technologies Global4.50%BWAYBrainsway19.00%DRTSAlpha Tau Medical39.50%INGNInogen1.46%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAVRAnteris Technologies Global13897.23 million92.86 millionN/ABWAYBrainsway12040.03 million32.43 millionNot OptionableDRTSAlpha Tau Medical8084.82 million51.32 millionNo DataINGNInogen1,03027.33 million26.93 millionOptionableINGN, DRTS, BWAY, and AVR HeadlinesRecent News About These CompaniesInogen Maintains Buy Rating as Analyst Reaffirms $12 Price Target on Solid Q1 and Growth CatalystsMay 8 at 6:11 AM | tipranks.comInogen (INGN) Q1 2026 Earnings TranscriptMay 7 at 12:27 AM | fool.comInogen Q1 Earnings Call HighlightsMay 7 at 12:05 AM | marketbeat.comInogen (INGN) Reports Q1 Loss, Beats Revenue EstimatesMay 7 at 8:11 PM | zacks.comInogen Announces First Quarter 2026 Financial ResultsMay 7 at 4:05 PM | businesswire.comInogen (INGN) Projected to Post Quarterly Earnings on ThursdayMay 5 at 4:27 AM | americanbankingnews.comInogen (INGN) Projected to Post Earnings on ThursdayApril 30, 2026 | marketbeat.comWe're Not Very Worried About Inogen's (NASDAQ:INGN) Cash Burn RateApril 29, 2026 | finance.yahoo.comInogen (NASDAQ:INGN) Stock Price Passes Above 50 Day Moving Average - Here's What HappenedApril 24, 2026 | marketbeat.comInogen to Report First Quarter 2026 Financial Results on May 7, 2026April 24, 2026 | finance.yahoo.comHere's Why You Should Retain Inogen Stock in Your Portfolio for NowApril 22, 2026 | zacks.comInogen Unveils Growth Plan at Needham Conference: New CFO, Voxi 5, Simeox and Aurora Mask PushApril 16, 2026 | marketbeat.comFreedom Capital Upgrades Inogen (NASDAQ:INGN) to Strong-BuyApril 8, 2026 | marketbeat.comInogen (INGN) Surges 6.9%: Is This an Indication of Further Gains?April 8, 2026 | zacks.comFreedom Broker initiates coverage of Inogen (INGN) with buy recommendationApril 8, 2026 | msn.comInogen Appoints Jamali to Board, Enters Cooperation Agreement With Activist InvestorApril 6, 2026 | marketwatch.comInogen Announces the Appointment of Vafa Jamali to Board of DirectorsApril 6, 2026 | businesswire.comInogen makes three appointments to exec teamMarch 31, 2026 | hmenews.comHInogen Announces Participation in the 25th Annual Needham Virtual Healthcare ConferenceMarch 31, 2026 | businesswire.comInogen Announces Leadership Appointments Designed to Accelerate Next Phase of GrowthMarch 30, 2026 | lasvegassun.comLInogen, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 30, 2026 | businesswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesWith Nike Shares Near a 12-Year Low, Is Now the Time to Be Brave?By Sam Quirke | April 12, 20263 Dividend Aristocrats Whose Yields Can Help Combat InflationBy Chris Markoch | April 9, 2026The War Won't Last Forever: 3 Stocks That Could Lead the RecoveryBy Bridget Bennett | April 8, 20265 Stocks Positioned to Win the AI Data Center BuildoutBy Bridget Bennett | April 20, 2026These 3 ETFs Are Suitable for Ultra-Bearish InvestorsBy Nathan Reiff | April 11, 2026INGN, DRTS, BWAY, and AVR Company DescriptionsAnteris Technologies Global NASDAQ:AVR$6.32 -0.20 (-3.00%) As of 11:15 AM Eastern This is a fair market value price provided by Massive. Learn more.Anteris Technologies Global Corp. engages in the development and commercialization of medical devices for heart diseases. The company was founded in 1999 and is headquartered in Eagan, MN.Brainsway NASDAQ:BWAY$17.10 +0.39 (+2.36%) As of 11:15 AM Eastern This is a fair market value price provided by Massive. Learn more.BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases. The company serves doctors, hospitals, and medical centers in the field of psychiatry. BrainsWay Ltd. was founded in 2003 and is headquartered in Jerusalem, Israel.Alpha Tau Medical NASDAQ:DRTS$8.02 +0.18 (+2.23%) As of 11:15 AM Eastern This is a fair market value price provided by Massive. Learn more.Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, prostate, and breast cancers; and preclinical studies for brain, hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. The company was incorporated in 2015 and is headquartered in Jerusalem, Israel.Inogen NASDAQ:INGN$7.34 +0.15 (+2.02%) As of 11:15 AM Eastern This is a fair market value price provided by Massive. Learn more.Inogen, Inc., a medical technology company, develops, manufactures, and markets portable oxygen concentrators to patients, physicians and other clinicians, and third-party payors in the United States and internationally. Its oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions. The company offers Inogen One, a portable device that concentrate the air around the patient to provide a source of supplemental oxygen; Inogen At Home stationary oxygen concentrators; Simeox airway clearance; batteries; and related accessories. It also rents its products directly to patients. Inogen, Inc. was incorporated in 2001 and is headquartered in Goleta, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Dutch Bros Q1 Earnings: The Newest Starbucks Rival Faces Its First Big Reality Check The AI Fear Around Datadog Stock May Have Been Completely Wrong Amprius Technologies Ups the Voltage on Forward Outlook Why Lam Research Still Looks Like a Buy After a 300% Rally Wells Fargo’s Comeback Is Real—But Not Risk-Free IonQ Just Posted a Breakout Quarter—But 1 Problem Remains SLB’s Tough Quarter Masks a Powerful Long-Term Shift Super Micro Surges Over 20% as Margins Soar, Sales Fall Short Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
